HomeCompareIMGI vs ABBV

IMGI vs ABBV: Dividend Comparison 2026

IMGI yields 8333333.33% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IMGI wins by $7.691208561253763e+45M in total portfolio value
10 years
IMGI
IMGI
● Live price
8333333.33%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$7.691208561253763e+45M
Annual income
$7,691,027,008,283,142,000,000,000,000,000,000,000,000,000,000,000,000.00
Full IMGI calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — IMGI vs ABBV

📍 IMGI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIMGIABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IMGI + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IMGI pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IMGI
Annual income on $10K today (after 15% tax)
$708,333,333.33/yr
After 10yr DRIP, annual income (after tax)
$6,537,372,957,040,671,000,000,000,000,000,000,000,000,000,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, IMGI beats the other by $6,537,372,957,040,671,000,000,000,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IMGI + ABBV for your $10,000?

IMGI: 50%ABBV: 50%
100% ABBV50/50100% IMGI
Portfolio after 10yr
$3.845604280626881e+45M
Annual income
$3,845,513,504,141,571,000,000,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
100.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

IMGI
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IMGI buys
0
ABBV buys
0
No recent congressional trades found for IMGI or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIMGIABBV
Forward yield8333333.33%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$7.691208561253763e+45M$102.3K
Annual income after 10y$7,691,027,008,283,142,000,000,000,000,000,000,000,000,000,000,000,000.00$24,771.77
Total dividends collected$7.69119668371173e+45M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: IMGI vs ABBV ($10,000, DRIP)

YearIMGI PortfolioIMGI Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$833,344,033$833,333,333.33$11,550$430.00+$833.33MIMGI
2$64,903,074,959,528$64,902,183,281,412.24$13,472$627.96+$64903074.95MIMGI
3$4,724,141,050,762,790,000$4,724,071,604,472,582,000.00$15,906$926.08+$4724141050762.77MIMGI
4$321,363,913,986,806,200,000,000$321,358,859,155,881,900,000,000.00$19,071$1,382.55+$321363913986806208.00MIMGI
5$20,430,926,468,170,230,000,000,000,000$20,430,582,608,782,265,000,000,000,000.00$23,302$2,095.81+$2.043092646817023e+22MIMGI
6$1,213,935,878,245,691,600,000,000,000,000,000$1,213,914,017,154,370,600,000,000,000,000,000.00$29,150$3,237.93+$1.2139358782456916e+27MIMGI
7$67,409,359,968,130,150,000,000,000,000,000,000,000$67,408,061,056,740,430,000,000,000,000,000,000,000.00$37,536$5,121.41+$6.740935996813015e+31MIMGI
8$3,498,335,588,078,376,400,000,000,000,000,000,000,000,000$3,498,263,460,063,210,600,000,000,000,000,000,000,000,000.00$50,079$8,338.38+$3.498335588078376e+36MIMGI
9$169,675,673,476,204,440,000,000,000,000,000,000,000,000,000,000$169,671,930,257,125,210,000,000,000,000,000,000,000,000,000,000.00$69,753$14,065.80+$1.6967567347620445e+41MIMGI
10$7,691,208,561,253,762,000,000,000,000,000,000,000,000,000,000,000,000$7,691,027,008,283,142,000,000,000,000,000,000,000,000,000,000,000,000.00$102,337$24,771.77+$7.691208561253763e+45MIMGI

IMGI vs ABBV: Complete Analysis 2026

IMGIStock

Imaginon, Inc., an information technology company, focuses on developing and marketing broadband and wireless Internet and Intranet software systems. The company primarily offers ImaginVideo, a client-server application for the delivery and management of interactive video over TCP/IP networks. It also provides ImaginAuthor, a Windows-based authoring tool for creating interactive Windows Media video content; and outsourcing service for the hosting of video content to a service provider running Windows 2000 Servers. The company was founded in 1996 and is based in San Carlos, California.

Full IMGI Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this IMGI vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IMGI vs SCHDIMGI vs JEPIIMGI vs OIMGI vs KOIMGI vs MAINIMGI vs JNJIMGI vs MRKIMGI vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.